Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252263 | 0.91 | MAP4K4 (0.37) | MAP4K4ABL1MAPK14 | |
| SCHEMBL26771045 | 0.88 | MAP4K4 (0.36) | MAP4K4 | |
| Formic Acid SCHEMBL30451900 | 0.85 | MAP4K4 (0.34) | MAP4K4ABL1MAPK14 | |
| Formic Acid SCHEMBL25268266 | 0.85 | MAP4K4 (0.34) | MAP4K4ABL1MAPK14 | |
| SCHEMBL26771000 | 0.85 | — | — | |
| SCHEMBL26771008 | 0.85 | DHFR (0.40) | MAP4K4 | |
| SCHEMBL26771076 | 0.84 | ABL1 (0.33) | ABL1 | |
| SCHEMBL25214927 | 0.83 | MAP4K4 (0.33) | MAP4K4ABL1MAPK14 | |
| SCHEMBL26771168 | 0.83 | — | — | |
| SCHEMBL26771089 | 0.82 | DHFR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | MAP4K4 2769/4885ABL1 4687/4885MAPK14 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.